To report a case of reversible nonthrombocytopenic palpable purpura associated with metoclopramide.
M etoclopramide has a variety of indications, including gastrointestinal motility disorders, chemotherapy-induced vomiting, gastroesophageal reflux, and diabetic gastroparesis. Classified as a benzamide, it is structurally similar to procainamide, but lacks any significant local anesthetic or antiarrhythmic actions. Its effects on the central nervous system and gastrointestinal system are apparently mediated by dopaminergic blockade. Rash and methemoglobinemia are rarely reported compared with the more common adverse effects such as restlessness, drowsiness, diarrhea, and extrapyramidal reactions. 1 Although the manufacturer 1 of metoclopramide has reported maculopapular rashes, purpuric eruptions such as those displayed by this patient have not been reported. This is a report of a patient who apparently experienced reversible nonthrombocytopenic palpable purpura related to the oral administration of metoclopramide.
CASE REPORT
A 72-year-old white man presented to the emergency department with "patching" on his legs that had progressively worsened over the past two days. He did not report pruritus or pain from the skin eruption. Vital signs and temperature were within normal limits. Physical examination revealed an extensive noncontiguous red patchy palpable skin eruption covering approximately 80% of the patient's lower extremities. The skin eruptions did not blanch on depression; thus, purpura was suspected rather than a local vasodilatory reaction. The patient had mild pedal edema, presumed secondary to congestive heart failure, consistent with an examination performed two days previously.
The patient was started on metoclopramide 10 mg orally three times daily two days prior to admission for relief of abdominal pain, presumably secondary to diabetic gastroparesis. Other outpatient medications included digoxin 0.125 mg/d, albuterol 2 puffs every four hours, amlodipine 5 mg/d, aspirin 325 mg/d, beclomethasone 2 puffs every four hours, furosemide 80 mg two times daily, ipratropium bromide 2 puffs every four hours, insulin (70/30) 80 units every morning and 40 units every evening, and gemfibrozil 600 mg twice daily. The patient reported no known drug allergies. Except for metoclopramide, all other medications had been taken chronically for the last year without significant changes.
The patient's past medical history was significant for congestive heart failure, type 1 diabetes, hypertension, chronic obstructive pulmonary disease (requiring home oxygen), and gastroparesis apparently secondary to diabetes. The patient had a 150 pack/year history of smoking, but quit two years ago. In addition, he drank 12 beers per day for 20 years, but stated that he quit two years ago as well. Laboratory reports on admission were white blood cell count 8.8 × 10 3 /mm 3 (normal 4-10), platelets 368 × 10 3 /mm 3 (150-450), hemoglobin 11.2 g/dL (14-18), hematocrit 33.2% (36-54), glucose 197 mg/dL (60-110), and serum creatinine 2.9 mg/dL (0.7-1.4). All other routine tests were within normal limits.
Metoclopramide was discontinued on admission to the hospital and all other outpatient medications were continued. Over the next two days, there was a significant reduction in the extent of purpura over the patient's extremities. No specific therapy was required to aid in the resolution of the reaction. A platelet count was not obtained prior to discharge since the admission value was within normal limits. The patient displayed no signs and symptoms of bleeding and, since the initial platelet count was within normal limits, no other tests for coagulation were ordered. Purpura began to resolve shortly after admission; thus, dermatology was not consulted and a skin biopsy was not obtained. The patient was not rechallenged with metoclopramide and, since he had no abdominal pain, no other treatment was initiated. No other complications developed during the patient's three days of hospitalization.
Discussion
Metoclopramide was first introduced in the 1960s as an antiemetic. Since then, many adverse effects have been reported to the manufacturer and documented in the literature. When Pinder et al. 2 reviewed the literature on the use and pharmacologic properties of metoclopramide in 1976, the only dermatologic effect noted was an urticarial or maculopapular rash. In 1982, a case of thrombocytopenic purpura related to metoclopramide was reported. 3 A reaction associated with metoclopramide similar to that experienced by our patient was not found in either MEDLINE or International Pharmaceutical Abstracts. Although causality is difficult to prove, it is reasonable to postulate that the purpura experienced by this patient was associated with metoclopramide. The timing of the purpura coincided with the initiation of metoclopramide and resolution occurred shortly after its discontinuation. All other medications had been used chronically for the past year by the patient and were continued upon admission. A literature search did not reveal an apparent relationship between the patient's reversible nonthrombocytopenic palpable purpuric reaction and any of the other medications he was taking.
Purpura is characterized by extravasation of red blood cells into the dermis; thus, unlike erythema and telangiectasia, it does not blanch with pressure. Purpura can be divided into three main categories. 4 The first category is intravascular and is usually accompanied by nonpalpable purpura. Aspirin and methyldopa have been associated with this type of purpura. The second category is known as extravascular or miscellaneous and may be palpable or nonpalpable. Possible etiologies of this category include toxins, venoms, scurvy, and corticosteroids (usually reported as nonpalpable). 5 Although the patient in this case report was using inhaled beclomethasone, a topical corticosteroid, it is unlikely that this was the cause of his purpura as he had been using it for more than a year; reactions with corticosteroids usually present as nonpalpable purpura, and systemic absorption is minimal. The third category is termed vascular and is usually characterized by palpable purpura. In fact, one of the most likely causes of palpable purpura is inflammatory small-vessel vasculitis. 6 This type of purely cutaneous vasculitis is often associated with drugs such as penicillin, sulfonamides, and phenytoin. 4 Symptoms may include pruritus, burning and, less often, pain, but the presence or absence of these symptoms is not considered integral to the diagnosis. 4 This patient most likely had an inflammatory vascular cutaneous reaction. The lack of thrombocytopenia, temporal association with a drug, and palpable nature of the purpura further supports this description.
Procainamide, an antiarrhythmic agent, is classified as an alkaloid with a substituted amide linkage. This structure is consistent with that of the benzamides, notably metoclo-pramide. Structural similarities between different classes of drugs may help explain similarities in adverse effect profiles. For instance, procainamide was associated with a purpuric ecchymotic eruption in a 74-year-old man. 7 This patient had a normal platelet count, but the thromboplastin time was elevated. In a case series by Knox et al., 8 urticarial vasculitis was associated with procainamide therapy in two men (aged 70 and 74 y). In the latter case, the rash began to resolve on day 3 after discontinuing procainamide and in the former case, resolution occurred four days after discontinuation. The mechanism of this adverse reaction is not well understood. One might speculate that since metoclopramide and procainamide are structurally similar, the reaction noted in our patient might be expected based on similar reactions reported with procainamide.
This case report illustrates a previously unreported case of reversible nonthrombocytopenic vascular-type palpable purpura. Clinicians may want to be aware of structural similarities between drugs and drug classes when evaluating previously undocumented reactions to identify and manage them appropriately.
I acknowledge the help of Tina Eng PharmD, who was a pharmacy student at the time.
EXTRACTO OBJETIVO: Reportar un caso de púrpura palpable no trombocitopénica asociada a metoclopramida. RESUMEN DEL CASO: Un hombre de 72 años se admitió al hospital debido a púrpura palpable que había empeorado en un período de 2 días. Dos días antes de la admisión el paciente se había comenzado en metoclopramida 10 mg tres veces al día para una condición gastrointestinal. Todos los fármacos fueron continuados al admitirse el paciente, excepto la metoclopramida. Dentro de los próximos 2 días la púrpura comenzó a resolver. El contaje de plaquetas estaba dentro de los limites normales al admitirse el paciente y éste no sufrio consecuencias serias debido a la púrpura.
DISCUSIÓN:
De acuerdo a la literatura disponible no se ha reportado previamente un caso de púrpura palpable reversible no trombocitopénica debido a metoclopramida. Una búsqueda en MEDLINE (1966-1998) y Extractos Farmacéuticos Internacionales no reveló un caso similar. Aunque el fármaco no se volvió a administrar al paciente, este caso parece demostrar una relación temporal entre el inicio y la terminación de la terapia con metoclopramida y el comienzo y la resolución de síntomas. Se han reportado casos similares en la literatura con procainamida la cual es estructuralmente similar a metoclopramida. CONCLUSIONES: Metoclopramida puede causar púrpura palpable reversible del tipo vascular no trombocitopénica. El descontinuar el fármaco pareció ser responsable por la resolución de síntomas.
JUAN F FELIÚ RÉSUMÉ
OBJECTIF: Rapporter un cas de purpura non-thrombocytopénique palpable et réversible associé au métoclopramide. RÉSUMÉ DU CAS: Un homme de 72 ans fut admis pour une exacerbation de purpura palpable survenue sur une période de 2 jours. Deux jours avant son admission, le patient a débuté un traitement avec du métoclopramide 10 mg po tid pour soulager ses symptômes digestifs, probablement causés par une gastroparésie diabétique. À l'admission, tous les médicaments du patient ont été continués, à l'exception du métoclopramide. Au cours des 2 jours suivants, le purpura a commencé à se résorber. À l'admission, le décompte plaquettaire était dans les limites de la normale et le patient n'a subi aucune séquelle sérieuse du purpura. DISCUSSION: Selon la littérature disponible, un purpura nonthrombocytopénique palpable et réversible n'a jamais été rapporté avec le métoclopramide. Une recherche dans les banques de données MEDLINE (1966-1998) et International Pharmaceutical Abstracts n'a révélé aucun cas semblable. Quoiqu'une réexposition au métoclopramide n'ait pas été tentée, on a pu observer une relation temporelle entre le début et l'arrêt du métoclopramide, de même qu'entre l'apparition et la résolution des symptômes. La littérature comporte des cas similaires survenus avec la procainamide, un analogue structurel du métoclopramide. CONCLUSIONS: Le métoclopramide peut causer un purpura nonthrombocytopénique de type vasculaire, palpable, et réversible. Dans ce cas-ci, l'arrêt du médicament semble être responsable de la résolution des symptômes.
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